Journal
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
Volume 13, Issue 7, Pages 805-814Publisher
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jbn.2017.2400
Keywords
Epigallocatechin-3-Gallate (EGCG); 3-Mercapto-1-Hexanol; Nanocomplexes; beta-Lactoglobulin; Tumor Inhibition
Funding
- Fund for Distinguished Scholars of Zhejiang Agricultural and Forestry University [2014FR064]
- National Natural Science Foundation of China [31270724]
- National Key Technology RD Program [2012BAD36B06]
- Natural Science Foundation of Zhejiang Province [LZ12C16004]
- Scientific Research Foundation for Talent program of Zhejiang Agricultural and Forestry University [W20170029]
Ask authors/readers for more resources
(-)-Epigallocatechin-3-gallate (EGCG), as the major catechin in green tea, is a potent antioxidant with numerous reported health benefits such as anti-proliferative and pro-apoptotic effects. Nanovehicles for EGCG delivery can effectively improve its antioxidant capacity, absorbability and bioavailability in vivo. We used thermally modified beta-lactoglobulin (beta-Lg), 3-mercapto-1-hexanol (3MH) and EGCG to form stable co-assembled nanocomplexes (ME beta-NPs) with greater stability, sustained release and anticancer effects in vitro and in vivo than free EGCG. ME beta-NPs inhibited A375, Hep G2 and TE-1 tumor cell proliferation with 65.90%, 60.44% and 32.88% greater activity, respectively, than EGCG. ME beta-NPs with 100 mg EGCG/kg (3MH/EGCG/beta-LG = 4: 32: 1) were not toxic to mice and inhibited implanted human melanoma A375 cell tumor growth by 57.78%, twice as effective as EGCG alone. Thus, ME beta-NPs have greater stability and antitumor activity than EGCG, with potential value for anticancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available